Clovis Oncology (CLVS) Stock Price, News & Analysis

Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.08 to $1.09
• 52-Week Range: N/A
• Volume: 1.16 million shs
• Average Volume: 8.88 million shs
• Market Capitalization: $11.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLVS Stock Analysis - Frequently Asked Questions

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) announced its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

• Last Earnings: 11/03/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLVS
• CUSIP: 18946410
• CIK: 1466301
• Web: www.clovisoncology.com
• Phone: 303-625-5000
• Fax: 303-245-0360
• Employees: N/A
• Year Founded: 2009

Profitability

• EPS (Most Recent Fiscal Year): ($1.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-264,520,000.00
• Net Margins: -189.37%
• Pretax Margin: -189.68%
• Return on Equity: N/A
• Return on Assets: -57.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $148.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.15) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 144,955,000
• Free Float: 138,577,000
• Market Cap: $11.60 million
• Optionable: Optionable
• Beta: 0.24